Research location

Kernersville

North Carolina, United States

Published trials43

Site observations43

Linked trials published43

Page1 / 1

Research activity in Kernersville

North Carolina, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 43 trials and 43 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Kernersville

43 linked trials · page 1 of 1

Distance-Based Exercise to Preserve Function and Prevent DisabilityNCT07059884 · 2026-02-11 · 1 site observation

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 1 site observation

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060 · 2025-03-14 · 1 site observation

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12 · 1 site observation

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)NCT04852887 · 2021-06-23 · 1 site observation

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 1 site observation

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 1 site observation

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline MutationNCT04711109 · 2023-02-14 · 1 site observation

ACTIVE_NOT_RECRUITING

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.NCT05492877 · 2022-11-14 · 1 site observation

Phase 4 COPD and Suboptimal Inspiratory Flow RateNCT05165485 · 2022-01-07 · 1 site observation

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation

ACTIVE_NOT_RECRUITING

National Cancer Institute "Cancer Moonshot Biobank"NCT04314401 · 2020-11-11 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung CancerNCT04214262 · 2020-08-13 · 1 site observation

ACTIVE_NOT_RECRUITING

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung CancerNCT04155034 · 2020-05-04 · 1 site observation

ACTIVE_NOT_RECRUITING

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyNCT04266249 · 2020-03-13 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)NCT03811002 · 2019-07-26 · 1 site observation

ACTIVE_NOT_RECRUITING

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)NCT03971474 · 2019-05-28 · 1 site observation

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT03845296 · 2019-04-16 · 1 site observation

Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast CancerNCT03633331 · 2018-08-15 · 1 site observation

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNCT02954874 · 2017-01-18 · 1 site observation

ACTIVE_NOT_RECRUITING

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyNCT02927249 · 2017-01-06 · 1 site observation

Palbociclib in Real World PracticeNCT03280303 · 2017-01-04 · 1 site observation

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)NCT02728596 · 2016-10-07 · 1 site observation

Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16 · 1 site observation

ACTIVE_NOT_RECRUITING

Avelumab in First-line NSCLC (JAVELIN Lung 100)NCT02576574 · 2015-10-29 · 1 site observation

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17 · 1 site observation

ACTIVE_NOT_RECRUITING

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With ChemotherapyNCT01901094 · 2014-02-24 · 1 site observation

ACTIVE_NOT_RECRUITING

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerNCT02003209 · 2014-02-18 · 1 site observation

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)NCT01988571 · 2014-02-01 · 1 site observation

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate CancerNCT01949337 · 2014-01-22 · 1 site observation

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerNCT01674140 · 2013-09-12 · 1 site observation

ACTIVE_NOT_RECRUITING

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone TherapyNCT01598298 · 2013-05-15 · 1 site observation

Cooperative Lifestyle Programs (CLIP-II)NCT01547182 · 2012-03-01 · 1 site observation

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerNCT01275677 · 2011-02-08 · 1 site observation

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung CancerNCT00977561 · 2010-04-01 · 1 site observation

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel ChemotherapyNCT00676650 · 2008-07-01 · 1 site observation

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and EtoposideNCT00632853 · 2008-03-01 · 1 site observation

Efficacy And Safety Of Sunitinib In Women With Advanced Breast CancerNCT00471276 · 2007-08-01 · 1 site observation

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or ExerciseNCT00118690 · 2003-12-01 · 1 site observation

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By ExemestaneNCT00036270 · 2001-08-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.